Mutations within the rplD Gene of Linezolid-Nonsusceptible Streptococcus pneumoniae Strains Isolated in the United States

被引：14

作者：

Dong, W. ^{[1
]}

Chochua, S. ^{[1
]}

McGee, L. ^{[2
]}

Jackson, D. ^{[2
]}

Klugman, K. P. ^{[1
]}

Vidal, J. E. ^{[1
]}

机构：

[1] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA

[2] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 04期

关键词：

RESISTANT STAPHYLOCOCCUS-AUREUS; RIBOSOMAL-PROTEIN L4; SURVEILLANCE PROGRAM; IN-VITRO; 1ST REPORT; LEADER PROGRAM; CFR; MECHANISM; CHLORAMPHENICOL; SPECTRUM;

D O I：

10.1128/AAC.02630-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Three invasive Streptococcus pneumoniae strains nonsusceptible to linezolid were isolated in the United States between 2001 and 2012 from the CDC's Active Bacterial Core surveillance. Linezolid binds ribosomal proteins where structural changes within its target site may confer resistance. Our study identified mutations and deletions near the linezolid binding pocket of two of these strains within the rplD gene, which encodes ribosomal protein L4. Mutations in the 23S rRNA alleles or the rplV gene were not detected.

引用

页码：2459 / 2462

页数：4

共 32 条

[1] [Anonymous], 2013, WAYNE PENNSYLVANIA C
[2] Linezolid resistance in Staphylococcus aureus:: Gene dosage effect, stability, fitness costs, and cross-resistances
Besier, Silke
Ludwig, Albrecht
Zander, Johannes
Brade, Volker
Wichelhaus, Thomas A.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1570 - 1572
[3] Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program
Biedenbach, Douglas J.
Farrell, David J.
Mendes, Rodrigo E.
Ross, James E.
Jones, Ronald N.
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 68 (04) : 459 - 467
[4] Oxazolidinones: activity, mode of action, and mechanism of resistance
Bozdogan, B
Appelbaum, PC
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (02) : 113 - 119
[5] CLINICAL LABORATORY STANDARDS INSTITUTE, 2009, M7A8 CLSI
[6] In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program
Draghi, DC
Sheehan, DJ
Hogan, P
Sahm, DF
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 5024 - 5032
[7] Linezolid surveillance program results for 2008 (LEADER Program for 2008)
Farrell, David J.
Mendes, Rodrigo E.
Ross, James E.
Jones, Ronald N.
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 65 (04) : 392 - 403
[8] In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations
Farrell, DJ
Morrissey, I
Bakker, S
Buckridge, S
Felmingham, D
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) : 3169 - 3171
[9] Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance
Feng, Jie
Lupien, Andreanne
Gingras, Helene
Wasserscheid, Jessica
Dewar, Ken
Legare, Danielle
Ouellette, Marc
[J]. GENOME RESEARCH, 2009, 19 (07) : 1214 - 1223
[10] Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011
Flamm, Robert K.
Mendes, Rodrigo E.
Ross, James E.
Sader, Helio S.
Jones, Ronald N.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (02) : 1077 - 1081

← 1 2 3 4 →